HPAAC: A Call for Safe and Transparent Use of…
The Healthcare Professionals Alliance Against COVID-19, the alliance of more than 160 health professions organizations in the country, is alarmed that some Filipinos are receiving vaccines against COVID-19 that have not been registered with the Philippine Food and Drug Administration (FDA). In relation to this issue, there are three critical points of concern:
1. In keeping with public safety, we strongly discourage the use of vaccines that are not yet approved by the Philippine FDA.
2. Even if a vaccine is approved in other countries, its storage, transport, and distribution are complex procedures. Improper handling can damage vaccines and can render them useless. This is why distribution channels and processes need to be transparent and regulated.
Read more “HPAAC: A Call for Safe and Transparent Use of COVID-19 Vaccines”
What is the sensitivity of SARS-CoV-2 RT-PCR done on…
For any questions or information, please email covidrapidreviewteam@gmail.com.
clinical specimen pediatric abridged>> Return to Rapid Reviews list.
What clinical characteristics and patient symptoms are associated with…
For any questions or information, please email covidrapidreviewteam@gmail.com.
clinical outcomes pediatric Abridged>> Return to Rapid Reviews list.
Interim Guidance on the Clinical Management of Adult Patients…
> NOTE: The COVID-19 Living Clinical Practice Guidelines contains UPDATED recommendations and evidence summaries. Click here to be redirected to the COVID LCPG.
This Interim Guidance on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection (Version 3.1) is an update of the March 31, 2020 guidelines released by the Philippine Society for Microbiology and Infectious Diseases. New evidence have been published since then necessitating this update.This document is written to guide clinicians and health care workers in their COVID-19 related management decisions. It is based on available scientific evidence that is also rapidly evolving, as more is discovered about the pathophysiology of SARS CoV-2 and the pathogenesis of the disease. As such, the recommendations in this guideline are based on limited, often low-quality evidence, and need to be carefully balanced with clinical judgment. The use of investigational drugs should be discussed with the patient or a legally authorized representative carefully outlining the potential adverse reactions and the potential clinical benefits of these investigational drugs. A signed informed consent should be obtained by the clinician.
DOWNLOAD the Interim Management Guidelines for COVID-19 (Version 3.1) here.
Final PCP-PSMID-PCCP COVID-19 Guidelines 20July2020b
Management of Patients with Probable or Confirmed COVID-19
Here is the latest treatment algorithm for the management of patients with probable or confirmed COVID-19.
Updated_COVID tx algorithm_July 20The Interim Management Guidelines for COVID-19 (Version 3.1) can be accessed here.